ABEO Earnings & Financial Statements
Abeona Therapeutics Inc.
$4.54
+$0.17(+4.01%)
45
Overall
80
Value
18
Tech
39
Quality
Market Cap
$249.32M
Volume
278.54K
52W Range
$4.00 - $7.65
Target Price
$19.14
ABEO earnings and financial statements: Abeona Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABEO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $5.82M | - | $3.50M | $1.41M | $3.00M |
| Cost of revenue | $3.42M | - | $1.60M | $450.0K | - |
| Operating income | -$89.45M | -$64.21M | -$47.13M | -$50.91M | -$89.84M |
| EBITDA | $78.59M | -$57.30M | -$61.95M | -$34.38M | -$76.82M |
| Net income | $71.18M | -$63.73M | -$54.19M | -$39.70M | -$84.94M |
| EPS (diluted) | $1.01 | $-1.55 | $-2.53 | $-5.53 | $-21.50 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $219.57M | $108.93M | $64.00M | $64.21M | $79.59M |
| Total liabilities | $60.35M | $64.90M | $49.18M | $37.45M | $37.22M |
| Shareholders’ equity | $159.22M | $44.03M | $14.83M | $26.76M | $42.37M |
| Cash and equivalents | $78.44M | $23.36M | $14.47M | $14.22M | $32.94M |
| Long-term debt | $11.88M | $16.30M | $4.40M | $5.85M | $7.56M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$76.33M | -$56.02M | -$37.01M | -$43.48M | -$65.67M |
| Capital expenditure | -$7.97M | -$2.43M | -$331.0K | -$130.0K | -$4.15M |
| Free cash flow | -$84.30M | -$58.46M | -$37.34M | -$43.61M | -$69.82M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABEO | $4.54 | +4.0% | 278.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Abeona Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW